Mesenchymal Stromal Cell Therapy in MDR/XDR Tuberculosis: A Concise Review

Archivum Immunologiae et Therapiae Experimentalis

Volumn 63, Issue 6, 2015, Pages 427-433

  Joshi, Lavanya ^a   Chelluri, Lakshmi Kiran ^b   Gaddam, Sumanlatha ^a,c  

^a Bhagwan Mahavir Medical Research Centre   (India)

^b Aware Global Hospital   (India)

^c OSMANIA UNIVERSITY   (India)

Author keywords

Adjunct therapy; Clinical trials; Immunomodulation; Mesenchymal stem cell therapy

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ANTIGEN PRESENTING CELL; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL CONTACT; CELL DIFFERENTIATION; CELL INTERACTION; CHRONIC INFLAMMATION; CONSERVATIVE TREATMENT; CYTOKINE PRODUCTION; DENDRITIC CELL; ENVIRONMENTAL FACTOR; EPIGENETICS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MESENCHYMAL STROMAL CELL TRANSPLANTATION; MICROENVIRONMENT; MULTIDRUG RESISTANT TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; ANIMAL; CLINICAL TRIAL (TOPIC); GENETIC EPIGENESIS; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; PROCEDURES; REGENERATION; STROMA CELL; TRANSPLANTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; EPIGENESIS, GENETIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; REGENERATION; STROMAL CELLS; T-LYMPHOCYTES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84946490310     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-015-0347-9     Document Type: Review

References (63)

1. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815–1822
2. Augello A, Tasso R, Negrini SM et al (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35:1482–1490
3. Bingisser RM, Tilbrook PA, Holt PG et al (1998) Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 160:5729–5734
4. Caplan AI, Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98:1076–1084
5. Chelluri LK, Prasad CE, Preethi V et al (2010a) Tumor necrosis factor (alpha) and Interferon-gamma in allogenic mixed cultures of haematopoetic and non-haematopoeitic cell-cell interactions; TB a case study. Internet J Infect Dis 8(1)
6. Chelluri LK, Prasad CE, Preethi V et al (2010b) Preliminary report on immunomodulation of mesenchymal stem cells in patients with tuberculosis infection. Cytotherapy 12(Suppl 1):55
7. Corcione A, Benvenuto F, Ferretti E et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367–372
8. Deans RJ, Moseley AB (2000) Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 28:875–884
9. Di Nicola M, Carlo-Stella C, Magni M et al (2002) Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838–3843
10. English K, Ryan JM, Tobin L et al (2009) Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25(high) forkhead box P3+ regulatory T cells. Clin Exp Immunol 156:149–160
11. Erices A, Conget P, Minguell JJ (2000) Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 109:235–242
12. Erokhin VV, Vasil’eva IA, Konopliannikov AG et al (2008) Systemic transplantation of autologous mesenchymal stem cells of the bone marrow in the treatment of patients with multidrug-resistant pulmonary tuberculosis. Probl Tuberk Bolezn Legk 10:3–6
13. Friedenstein AJ (1976) Precursor cells of mechanocytes. Int Rev Cytol 47:327–359
14. Friedenstein AJ, Petrakova KV, Kurolesova AI et al (1968) Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6:230–247
15. Glennie S, Soeiro I, Dyson PJ et al (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105:2821–2827
16. Groh ME, Maitra B, Szekely E et al (2005) Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 33:928–934
17. Gronthos S, Franklin DM, Leddy HA et al (2001) Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol 189:54–63
18. Herzog EL, Chai L, Krause DS (2003) Plasticity of marrow-derived stem cells. Blood 102:3483–3493
19. Hoffman RA, Mahidhara RS, Wolf-Johnston AS et al (2002) Differential modulation of CD4 and CD8 T-cell proliferation by induction of nitric oxide synthesis in antigen presenting cells. Transplantation 74:836–845
20. Huang W, La Russa V, Alzoubi A et al (2006) Interleukin-17A: a T-cell derived growth factor for murine and human mesenchymal stem cells. Stem Cells 24:1512–1518
21. in’t Anker PS, Noort WA, Kruisselbrink AB et al (2003a) Non-expanded primary lung and bone marrow-derived mesenchymal stem cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in the NOD/SCID mice. Exp Hematol 31:881–889
22. in’t Anker PS, Scherjon SA, Klejiburg-van der Keur C et al (2003b) Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 102:1548–1549
23. Ivanova-Todorova E, Bochev I, Mourdjeva M et al (2009) Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett 126:37–42
24. Javazon EH, Beggs KJ, Flake AW (2004) Mesenchymal stem cells: paradoxes of passaging. Exp Hematol 32:414–425
25. Jiang XX, Zhang Y, Liu B et al (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105:4120–4126
26. Krampera M, Glennie S, Dyson J et al (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen specific T cells to their cognate peptide. Blood 101:3722–3729
27. Krampera M, Cosmi L, Angeli R et al (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386–398
28. Le Blanc K, Ringdén O (2006) Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 18:586–591
29. Le Blanc K, Ringdén O (2007) Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262:509–525
30. Le Blanc K, Tammik C, Rosendahl K et al (2003a) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31:890–896
31. Le Blanc K, Tammik L, Sundberg B et al (2003b) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11–20
32. Lin PL, Flynn JL (2010) Understanding latent tuberculosis: a moving target. J Immunol 185:115–122
33. Lin H, Xu R, Zhang Z et al (2011) Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases. Cell Mol Immunol 8:19–22
34. Maccario R, Podesta M, Moretta A et al (2005) Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90:516–525
35. Meisel R, Zibert A, Laryea M et al (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase mediated tryptophan degradation. Blood 103:4619–4621
36. Migliori G, Loddenkemper R, Blasi F et al (2007) 125 years after Robert Koch’s discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic? Eur Respir J 29:423–427
37. Moretta A, Bottino C, Vitale M et al (2001) Activating receptors and co-receptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197–223
38. Nauta AJ, Kruisselbrink AB, Lurvink E et al (2006) Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 177:2080–2087
39. Prockop DJ, Gregory CA, Spees JL (2003) One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA 100(Suppl 1):11917–11923
40. Raghuvanshi S, Sharma P, Singh S et al (2010) Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci USA 107:21653–21658
41. Rai RC, Bhattacharya D, Das G (2011) Stem cells in infectious diseases: insight and control of infectious disease in global scenario. ISBN 979-953-307-497-8. http://www.intechopen.com/books/insight-and-control-of-infectious-disease-in-globalscenario/stem-cells-in-infectious-diseases
42. Ramasamy R, Fazekasova H, Lam EW et al (2007) Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83:71–76
43. Rasmusson I, Ringden O, Sundberg B et al (2003) Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76:1208–1213
44. Ren G, Zhang L, Zhao X et al (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2:141–150
45. Ren G, Su J, Zhang L et al (2009) Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27:1954–1962
46. Ren G, Zhao X, Zhang L et al (2010) Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184:2321–2328
47. Rush S (2010) Trinity Evolution: mesenchymal stem cell allografting in foot and ankle surgery. Foot Ankle Spec 3:140–143
48. Ryan JM, Barry FP, Murphy JM et al (2005) Mesenchymal stem cells avoid allogeneic rejection. J Inflamm 2:8
49. Ryan JM, Barry F, Murphy JM et al (2007) Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149:353–363
50. Salam MA (2010) MDR/XDR-TB: where do we stand? Bangladesh J Med Sci 9(4):189
51. Sato K, Ozaki K, Oh I et al (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109:228–234
52. Shi Y, Hu G, Su J et al (2010) Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 20:510–518
53. Skrahina A, Hurevich H, Zalutskaya A et al (2012) Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 39:1425–1431
54. Skrahina A, Ahmed RK, Ferrara G et al (2014) Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2:108–122
55. Sotiropoulou PA, Perez SA, Gritzapis AD et al (2006) Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24:74–85
56. Stagg J, Pommey S, Eliopoulos N et al (2006) Interferon-gamma-stimulated marrow stromal cells: a new type of non-hematopoietic antigen-presenting cell. Blood 107:2570–2577
57. Sudres M, Norol F, Trenado A et al (2006) Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 176:7761–7767
58. Uhlin M, Andersson J, Zumla A et al (2012) Adjunct immunotherapies for tuberculosis. J Infect Dis 205(Suppl 2):S325–S334
59. Von Lüttichau I, Notohamiprodjo M, Wechselberger A et al (2005) Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 14:329–336
60. WHO (2014) Global Tuberculosis Control Report 2014. World Health Organization, Geneva. http://www.who.int/tb/publications/global_report/en/. Accessed 12 Nov 2014
61. Wong RS (2011) Mesenchymal stem cells: angels or demons? J Biomed Biotechnol 2011:459510
62. Xu G, Zhang L, Ren G et al (2007) Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell Res 17:240–248
63. Zhang W, Ge W, Li C et al (2004) Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 13:263–271